

Adelya Hairullina

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6143539/adelya-hairullina-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

1,112
citations

11
h-index

18
g-index

18
ext. papers

1,329
ext. citations

6.4
avg, IF

3.66
L-index

#	Paper	IF	Citations
18	Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. <i>European Heart Journal</i> , 2012 , 33, 2831-40	9.5	474
17	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , 2016 , 388, 2142-2152	40	261
16	Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. <i>JAMA Internal Medicine</i> , 2014 , 174, 1651-9	11.5	84
15	Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. <i>PLoS ONE</i> , 2012 , 7, e36284	3.7	60
14	Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2013 , 167, 2938-43	3.2	48
13	Blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. <i>European Heart Journal</i> , 2019 , 40, 1399-1407	9.5	35
12	Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease. <i>American Journal of Medicine</i> , 2017 , 130, 720-730	2.4	29
11	Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2017 , 40, 797-806	3.3	29
10	Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. <i>International Journal of Cardiology</i> , 2014 , 176, 119-24	3.2	22
9	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020 , 41, 347-356	9.5	20
8	Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients. <i>PLoS ONE</i> , 2014 , 9, e102335	3.7	18
7	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. <i>PLoS ONE</i> , 2015 , 10, e0125164	3.7	9
6	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 426-436	3.9	9
5	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320918728	3.9	8
4	Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	4
3	Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry. <i>Polish Archives of Internal Medicine</i> , 2017 , 127, 107-114	1.9	2
2	Reply: Is the instantaneous wave-free ratio equivalent to fractional flow reserve?. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 943-5	15.1	0

- 1 Justification of treatment and possible outcomes of severe COVID-19. *Kazan Medical Journal*, **2021**, 102, 934-939

0.2